<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01578447</url>
  </required_header>
  <id_info>
    <org_study_id>00003213</org_study_id>
    <nct_id>NCT01578447</nct_id>
  </id_info>
  <brief_title>Acceptability of Depo-subQ Provera 104 in Uniject vs. Intramuscular Depo-Provera Among HIV+ Women &amp; Providers, Uganda</brief_title>
  <official_title>Acceptability of Depo-subQ Provera 104 in Uniject Versus Intramuscular Depo-Provera Among HIV-positive Women and Family Planning Providers in Rakai, Uganda</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins Bloomberg School of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rakai Health Sciences Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins Bloomberg School of Public Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess acceptability and side effects of a low-dose
      injectable contraceptive formulation which is delivered under the skin (subcutaneously), as
      compared with injectable contraception delivered into the muscle (intramuscularly) among
      adult HIV-positive women who attend mobile clinics for HIV care and wish to use injectable
      contraception. The investigators will also assess experiences experiences delivering these
      two types of injections among health care providers working within the HIV care clinics.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preferred injection method</measure>
    <time_frame>6 months</time_frame>
    <description>Preference for subcutaneous injection, intramuscular injection, or no preference between the two</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acceptability, satisfaction, and problems encountered with subcutaneous injection versus intramuscular injection, as reported by HIV/family planning care providers</measure>
    <time_frame>Baseline, 10 months</time_frame>
    <description>E.g., problems encountered, preference to give more, same amount, or fewer of each kind of injection, advantages and disadvantages of each kind of injection, difficulty of administration, perception of client experience, which type of injectable prefers to administer, whether preferences are impacted by HIV status of client</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypothetical acceptability of contraceptive injections provided by community health care worker, trained and trusted friend or family member, or self-administration</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
    <description>In this study, all injections will be provided by a trained medical professional, but we will ask women if they would hypothetically find provision by community health workers, a trained trusted friend or family member, or self-administration acceptable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy incidence</measure>
    <time_frame>3 months, 6 months</time_frame>
    <description>Will not be compared according to study product, since all participants will utilize both products in this crossover trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
    <description>Including pain/injection/soreness at injection site and other reported side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuation of use of injectables</measure>
    <time_frame>3 months, 6 months</time_frame>
    <description>Proportion of enrolled women who continue using injectable contraception at follow up visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Future use intentions</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
    <description>Whether plans to use injectable contraception again in three months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Likelihood of recommending method to a friend</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
    <description>How likely participant would be to recommend this contraceptive method to a friend</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of satisfaction with method</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
    <description>Level of satisfaction with method of contraception injection received</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">356</enrollment>
  <condition>Acceptability of Different Contraceptive Injection Types</condition>
  <arm_group>
    <arm_group_label>Depo-SubQ Provera 104 in Uniject</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intramuscular DMPA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DepoSubQ Provera 104 in Uniject</intervention_name>
    <description>DepoSubQ Provera 104 in Uniject</description>
    <arm_group_label>Depo-SubQ Provera 104 in Uniject</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intramuscular DMPA</intervention_name>
    <description>Intramuscular DMPA</description>
    <arm_group_label>Intramuscular DMPA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV+

          -  Woman aged 18-45

          -  Wishes to prevent pregnancy by use of injectable contraception and intends to continue
             using injectable contraception for next nine months

          -  Medically eligible for injectable contraception

          -  Capable of providing informed consent

          -  Willing to provide contact information

          -  Agrees to trial participation

          -  Intends to live in the area for the next nine months

          -  May or may not be currently using a first-line antiretroviral therapy regimen
             (includes: AZT/3TC/EFV; AZT/3TC/NVP; CBV/EFV; D4T/3TC/EFV; D4T/3TC/NVP; TDF/3TC/EFV;
             TDF/3TC/NVP)

        Exclusion Criteria:

          -  Currently pregnant

          -  Desires pregnancy within next nine months

          -  Contraindications to using injectable contraception

          -  On second-line antiretroviral therapy regimen
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ron H Gray, MD, MSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rakai Health Sciences Program</name>
      <address>
        <city>Kalisizo</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <link>
    <url>http://www.sciencedirect.com/science/article/pii/S0010782413006951</url>
    <description>abstract</description>
  </link>
  <results_reference>
    <citation>Polis CB, Nakigozi GF, Nakawooya H, Mondo G, Makumbi F, Gray RH; Members of the Rakai Health Sciences Program Sayana Press study team. Preference for SayanaÂ® Press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial. Contraception. 2014 May;89(5):385-95. doi: 10.1016/j.contraception.2013.11.008. Epub 2013 Nov 15.</citation>
    <PMID>24332432</PMID>
  </results_reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2012</study_first_submitted>
  <study_first_submitted_qc>April 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2012</study_first_posted>
  <last_update_submitted>September 16, 2014</last_update_submitted>
  <last_update_submitted_qc>September 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins Bloomberg School of Public Health</investigator_affiliation>
    <investigator_full_name>Ronald Gray</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>injectable contraception</keyword>
  <keyword>acceptability</keyword>
  <keyword>intramuscular</keyword>
  <keyword>subcutaneous</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

